TY - JOUR T1 - COMMD5 Inhibits Malignant Behavior of Renal Cancer Cells JF - Anticancer Research JO - Anticancer Res SP - 2805 LP - 2815 DO - 10.21873/anticanres.15061 VL - 41 IS - 6 AU - JIN IKEDA AU - HIROYUKI MATSUDA AU - MAIKO OGASAWARA AU - YUKIMOTO ISHII AU - KENYA YAMAGUCHI AU - SATORU TAKAHASHI AU - NOBORU FUKUDA AU - YOSHIKAZU MASUHIRO AU - MORITO ENDO AU - MASAYOSHI SOMA AU - PAVEL HAMET AU - JOHANNE TREMBLAY Y1 - 2021/06/01 UR - http://ar.iiarjournals.org/content/41/6/2805.abstract N2 - Background/Aim: Copper metabolism MURR1 domain-containing 5 (COMMD5) is mainly expressed in renal tubules (RTs), where it facilitates re-differentiation of injured RTs. We reported that COMMD5 regulates the expression of epidermal growth factor receptor by participating in its endocytic membrane trafficking, thus inhibiting tumor growth. Here we aimed to determine the role of COMMD5 in malignant phenotypes of renal cell carcinoma (RCC). Materials and Methods: The associations between COMMD5 levels in RTs adjacent to RCC tumors in patients and their clinicopathologic characteristics were evaluated, and the effects of COMMD5 on cancer stemness in RCC cells were investigated. Results: Low COMMD5 levels in RTs correlated with high tumorigenesis and poor patient outcomes. COMMD5 overexpression in RCC cells reduced the proportion of cancer stem cell-like cells and their malignant phenotypes, including proliferation, invasion and sphere formation. Secreted COMMD5 from RT cells also reduced malignant phenotypes. Conclusion: COMMD5 might suppress malignant phenotypes of RCC, thus inhibiting tumor development and improving patient prognosis. ER -